Evidence map›Paper›PMID 41016858›Full record

ArticlePest management science2026

Susceptibility to cyflumetofen in populations of the citrus leprosis mite, Brevipalpus yothersi, from Brazilian citrus orchards.

Hector Alonso Escobar-Garcia, Daniel Júnior de Andrade

Abstract read
In one paragraph

Article in Pest management science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hector Alonso Escobar-GarciaSão Paulo State University (UNESP), School of Agricultural and Veterinary Sciences, Jaboticabal, Brazil.ORCID https://orcid.org/0000-0002-5003-2268
Daniel Júnior de AndradeSão Paulo State University (UNESP), School of Agricultural and Veterinary Sciences, Jaboticabal, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível Superior
6 · The paper itself

Abstract

backgroundBrevipalpus yothersi Baker (Acari: Tenuipalpidae), the citrus leprosis mite, is currently the most economically significant mite pest in commercial citrus orchards, serving as the vector of citrus leprosis virus C (CiLV-C, Cilevirus leprosis). Its control has traditionally relied on the intensive use of synthetic acaricides, raising concerns regarding field efficacy and resistance development. To support integrated pest management (IPM) and resistance management strategies, monitoring the susceptibility of field populations is essential. Cyflumetofen, an acaricide that inhibits mitochondrial complex II electron transport, offers a distinct mode-of-action (MoA) for mite control. This study aimed to characterize the susceptibility of B. yothersi populations to cyflumetofen to evaluate its potential use in sustainable resistance management and prolong its efficacy in commercial applications.

resultsField populations exhibited high susceptibility to cyflumetofen, with median lethal concentration (LC

conclusionCyflumetofen proved effective against B. yothersi in the surveyed regions, with field populations showing high susceptibility. To maintain its efficacy and extend its commercial longevity, rotation with other synthetic acaricides featuring different MoAs is recommended as part of a resistance management plan. © 2025 The Author(s). Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

Indexed as

AcaricidesCitrusDrug ResistanceMitesPropionatesAnimalsBrazilAcaricidescyflumetofenPropionatesArcGISchemical controldiagnostic concentrationflat mitesoviposition reduction

Identifiers

PMID41016858
PMCPMC12713711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.